Table 5.
Ongoing clinical trials with relugolix in combination with ARPIs [48]
| Study title | NCT number | Phase |
|---|---|---|
| Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) | NCT06463457 | Phase 2 |
| Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer | NCT06631521 | Phase 1 |
| Relugolix + Enzalutamide Study in High-Risk Prostate Cancer | NCT06130995 | Phase 1 |
| REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial | NCT06650579 | Phase 3 |
| Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial | NCT06499870 | Phase 2 |
| Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial | NCT06378866 | Phase 2 |